01 / STACK OVERVIEW

The KLOW Protocol

      KLOW is Apex's flagship 4-compound recovery and anti-inflammatory stack. Where the Wolverine Stack (BPC-157 + TB-500) targets musculoskeletal injury, KLOW expands the coverage to include the gut, mucosal barriers, skin, and the entire inflammatory cascade. Four peptides, four distinct mechanisms, one coordinated protocol. This is the stack for systemic restoration.
    

KPV

20mg vial · 66.7 mcg/unit

GUT + MUCOSAL REPAIR

Tripeptide (Lys-Pro-Val) derived from α-MSH C-terminus. Potent anti-inflammatory — directly inhibits NF-κB and blocks pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6). Penetrates GI epithelium and crosses the blood-brain barrier. Heals leaky gut, colitis, inflammatory bowel disease, and skin inflammation.

TB-500

20mg vial · 66.7 mcg/unit

SYSTEMIC REPAIR + STEM CELLS

Thymosin Beta-4 fragment. Binds actin, promotes stem cell mobilization to injury sites, reduces systemic inflammation via NF-κB pathway. Works throughout the entire body — muscles, tendons, ligaments, cardiac tissue, neurological tissue. The systemic amplifier of the stack.

BPC-157

20mg vial · 66.7 mcg/unit

LOCAL REPAIR + GI PROTECTION

Body Protection Compound — activates VEGFR2, FGFR, and EGF receptors at injury sites. Accelerates angiogenesis, tendon-to-bone attachment, gut lining regeneration. Hepatoprotective (protects liver). Neuroprotective. Works locally — inject near target tissue.

GHK-Cu

50mg vial · 166.7 mcg/unit

COLLAGEN + SKIN + LONGEVITY

Copper tripeptide — naturally occurring in plasma, saliva, and urine. Activates 31 collagen/elastin genes, promotes wound closure, upregulates antioxidant enzymes (SOD, catalase). Anti-aging: resets gene expression toward a younger profile. Skin, hair follicle activation, bone density support.

80mg

TOTAL STACK

4

VIALS

4

MECHANISMS

12w

CYCLE LENGTH

Full

BODY COVERAGE

02 / SYNERGY LAYERS

Four Layers of Recovery

1

UPSTREAM INFLAMMATION CONTROL — KPV

KPV halts the inflammatory cascade at the source. NF-κB inhibition cuts off TNF-α, IL-1β, and IL-6 production — the upstream signals that drive chronic inflammation. Without this layer, the repair work done by BPC-157 and TB-500 constantly fights an active inflammatory environment. KPV creates the quiet the other peptides need to rebuild.

2

SYSTEMIC CELLULAR REPAIR — TB-500

With inflammation suppressed by KPV, TB-500 mobilizes stem cells and repair machinery throughout the entire body. Actin binding drives cellular motility — cells move to where they're needed. Every damaged tissue in the body gets reinforcements simultaneously. This is the systemic amplification layer.

3

LOCAL TISSUE RECONSTRUCTION — BPC-157

While TB-500 sends the army, BPC-157 directs the battle at the local level. VEGF-driven angiogenesis creates new blood supply to damaged tissue. Growth factor activation rebuilds the extracellular matrix. Tendon, gut wall, muscle, bone — BPC-157 leads local reconstruction at each specific site.

4

STRUCTURAL MATRIX + LONGEVITY — GHK-Cu

Once the acute repair is underway, GHK-Cu rebuilds the structural collagen and elastin matrix that gives repaired tissue its integrity and resilience. Simultaneously resets gene expression toward a younger, more regenerative profile. The finishing layer — not just repair, but rejuvenation of the entire extracellular architecture.

Net Effect: Inflammation off → repair cells mobilized → local reconstruction directed → structural matrix rebuilt. Each compound hands off to the next in a logical biological sequence. This is why KLOW outperforms any single peptide or two-peptide combination for systemic recovery.

⚠ CRITICAL · HOW TO MIX THIS STACK

GHK-Cu can degrade the other peptides if you mix them in one syringe

This is the most important thing to know about running the KLOW stack. GHK-Cu is a copper-peptide complex — the copper atom is what gives it biological activity. But copper is also redox-active, meaning it catalyzes oxidation reactions. When GHK-Cu sits in the same solution as BPC-157 or TB-500, the copper can oxidize methionine residues (especially in TB-500) — degrading those peptides over minutes to hours.

✅ SAFE TO CO-MIX IN ONE SYRINGE

KPV + BPC-157 + TB-500 — all three together
BPC-157 + TB-500 (the Wolverine combo)
BPC-157 + KPV
TB-500 + KPV

No copper, no metal catalyst, compatible buffers. Draw each into the same insulin syringe, inject together SubQ.

🚫 DO NOT CO-MIX

GHK-Cu + BPC-157
GHK-Cu + TB-500
GHK-Cu + KPV
GHK-Cu + anything

Copper catalyzes oxidation of methionine, cysteine, tryptophan. TB-500 is most vulnerable (has methionine). Even fresh co-mixing starts the clock on degradation.

BEST-PRACTICE PROTOCOL

Syringe 1 (evening): KPV + BPC-157 + TB-500 co-drawn into one insulin syringe, injected SubQ (belly fat).
Syringe 2 (morning OR different site): GHK-Cu alone, SubQ or as a topical cream.
Never pre-mix and store — draw into the syringe fresh each dose, inject within 5–10 minutes.
Order of draw (for co-mixed peptides): smallest volume first to minimize loss in the needle hub.

The copper-peptide oxidation mechanism is well-documented in pharmaceutical stability literature (Schöneich et al., various methionine-oxidation studies). While the degradation rate varies by concentration and temperature, the consensus is: don't mix copper-containing peptides with methionine-containing peptides if you want maximum potency from both.

03 / RECONSTITUTION

Vial Preparation — All Four Compounds

KPV — 20mg VIAL

20mg + 3.0 mL BAC water

66.7 mcg per unit

500mcg: 7.5 units / 0.075 mL

1mg: 15 units / 0.15 mL

2mg: 30 units / 0.30 mL

TB-500 — 20mg VIAL

20mg + 3.0 mL BAC water

66.7 mcg per unit

1mg: 15 units / 0.15 mL

2mg: 30 units / 0.30 mL

4mg: 60 units / 0.60 mL

BPC-157 — 20mg VIAL

20mg + 3.0 mL BAC water

66.7 mcg per unit

250mcg: 3.75 units / 0.0375 mL

500mcg: 7.5 units / 0.075 mL

1mg: 15 units / 0.15 mL

GHK-Cu — 50mg VIAL

50mg + 3.0 mL BAC water

166.7 mcg per unit

500mcg: 3 units / 0.03 mL

1mg: 6 units / 0.06 mL

2mg: 12 units / 0.12 mL

🧊

RECONSTITUTED SHELF LIFE

21 days after mixing

Multi-peptide stack. Shelf life = shortest member = 21 days.

            Storage: 2–8°C (fridge) · Protected from light · Do NOT freeze

            Preload syringes/cartridges to minimize vial disturbance

Storage (all vials): Lyophilized stable at room temp 6 months. Post-reconstitution: refrigerate (36–46°F / 2–8°C), use within 28–30 days. Protect from light. Do NOT freeze reconstituted vials. GHK-Cu may have blue-green color from copper — this is normal.

04 / DOSING PROTOCOL

Dose Ranges — All Four Compounds

COMPOUND	LOW DOSE	STANDARD DOSE	HIGH DOSE	FREQUENCY
KPV	500mcg/day	1mg/day	2mg/day	Daily SC or oral (stable in stomach)
TB-500	1mg/week	2mg/week	4mg/week	1–2 injections per week
BPC-157	250mcg/day	500mcg/day	750mcg/day	Daily (split AM/PM at high dose)
GHK-Cu	500mcg/day	1mg/day	2mg/day	Daily SC (or topical concurrent)

KPV Oral Note: KPV is uniquely stable to gastric acid — oral capsule form (from compounding pharmacy) is effective for gut/GI conditions. SC injection preferred for systemic anti-inflammatory effect. Both routes can be run concurrently.

GHK-Cu Topical Concurrent: Topical GHK-Cu cream can be used alongside SC injections for skin-specific goals. Topical reaches dermal layers directly; SC provides systemic collagen gene activation. Not redundant — additive for skin and wound healing outcomes.

05 / INJECTION SCHEDULE

Weekly Protocol

COMPOUND

DAILY SCHEDULE

SITE / NOTES

KPV

✓ 1mg every AM

SC abdominal / oral capsule for GI targeting

BPC-157

✓ 500mcg every AM (near injury site)

SC near damaged tissue; rotate periumbilical otherwise

TB-500

✓ 1mg Mon + 1mg Thu

Any SC site — systemic distribution, rotate locations

GHK-Cu

✓ 1mg every PM

SC any site; topical cream concurrent for skin goals

AM/PM Split: KPV + BPC-157 in the morning maximizes daytime tissue repair activity. GHK-Cu in the evening allows collagen gene upregulation during overnight regenerative sleep. TB-500 twice weekly — timing relative to other injections is flexible.

06 / BIOMARKER MONITORING

Recommended Lab Panel

INFLAMMATION — PRIMARY KLOW RESPONSE

MARKER	CLINICAL RANGE	OPTIMAL TARGET	NOTES
hs-CRPC-reactive protein (high-sensitivity)	CLINICAL<3.0 mg/L	OPTIMAL<0.5 mg/L	KPV + BPC-157 dual NF-κB inhibition should drive significant reduction. Recheck at 4 and 8 weeks.
IL-6interleukin-6	CLINICAL<7 pg/mL	OPTIMAL<1.8 pg/mL	KPV directly blocks IL-6 production. Most sensitive marker of KPV efficacy.
TNF-αtumor necrosis factor alpha	CLINICAL<8.1 pg/mL	OPTIMAL<2 pg/mL	KPV's primary target cytokine. Reduction here is the most direct readout of anti-inflammatory efficacy.

GUT & MUCOSAL HEALTH (KPV-SPECIFIC)

MARKER	CLINICAL RANGE	OPTIMAL TARGET	NOTES
Calprotectinfecal calprotectin	CLINICAL<50 µg/g	OPTIMAL<25 µg/g	GI inflammation marker. Elevated in IBD, colitis. KPV should drive significant reduction in GI conditions.
Zonulinintestinal permeability	CLINICAL<47 ng/mL	OPTIMAL<30 ng/mL	Leaky gut marker — KPV + BPC-157 together seal tight junctions and heal gut epithelium. Should improve.
sIgAsecretory immunoglobulin A	CLINICAL51–204 mg/dL	OPTIMALUpper normal	Mucosal immune defense marker — improvement indicates gut barrier restoration.

SKIN & COLLAGEN (GHK-Cu SPECIFIC)

MARKER	METHOD	NOTES
P1NPprocollagen type I N-terminal propeptide	Serum — baseline + 8 weeks	Collagen synthesis marker. GHK-Cu drives this up — confirms active collagen production at matrix level.
Skin Elasticitycutometer or visual assessment	Photography baseline + 8–12 weeks	Objective skin assessment — standardized lighting, same angle. GHK-Cu effects visible at 8–12 weeks.
Serum Coppercopper — serum	Baseline only	Confirm baseline copper status. GHK-Cu micro-doses copper — relevant if copper deficiency exists.

SAFETY PANEL

MARKER	CLINICAL RANGE	NOTES
CBC + CMPcomplete blood count + metabolic panel	CLINICALStandard	Baseline + 8 weeks. BPC-157 is hepatoprotective — liver values should remain stable or improve.

07 / CYCLE PROTOCOL

Administration Schedule

CYCLE LENGTH

12 Weeks

LOADING PHASE (Wks 1–4)

All 4 compounds at standard doses. TB-500 loading: 2mg 2×/week. KPV + BPC-157 daily. GHK-Cu daily. Prioritize inflammation control first — KPV sets the stage.

MAINTENANCE PHASE (Wks 5–12)

TB-500: 2mg 1×/week. All others continue at standard dose. Body is now in active repair and rebuilding mode. GHK-Cu effect on collagen genes becomes measurable in this window.

OFF PERIOD

4–8 weeks between full cycles. KPV and BPC-157 may be continued at low maintenance doses (500mcg/day each) for chronic inflammatory or GI conditions.

BEST CANDIDATES

Autoimmune conditions · Inflammatory bowel disease · Leaky gut / food sensitivities · Chronic musculoskeletal injury · Post-surgical recovery · Anti-aging / skin optimization · Active athletes seeking systemic restoration

REQUIRES

4 vials + BAC water + Apex V3 Pen. 2 injections per day (AM: KPV + BPC-157 · PM: GHK-Cu) + TB-500 2×/week = ~16 injections/week total. Manageable with Apex pen system.

⚠ Research reference only. KPV, TB-500, BPC-157, and GHK-Cu are not FDA-approved for human therapeutic use. Information sourced from published clinical and preclinical literature. Consult a qualified medical provider before use.